

Curriculum Vitae
Kristi D. Sutphin

Signature: 
Date Signed: 6/19/08

Business Address:

CAMC Health Education and
Research Institute
Clinical Trials Center
3100 MacCorkle Avenue, SE
Suite 306
Charleston, WV 25304
Phone: (304) 388-9945
Fax: (304) 388-9935
Email: kristi.sutphin@camc.org

EDUCATION:

1992 - 1996 Bachelors of Business Administration
 Major: Marketing Minor: Management Communications
 Marshall University
 Huntington, WV

1992 Diploma
 St. Albans High School
 St. Albans, WV

PROFESSIONAL EXPERIENCE:

2008 - Present Clinical Operations Manager
 CAMC Health Education and Research Institute, Inc.
 Charleston, WV

2004 - 2008 Clinical Trials Financial Analyst
 CAMC Health Education and Research Institute, Inc.
 Charleston, WV

2001 - 2004 Clinical Research Study Coordinator
 CAMC Health Education and Research Institute, Inc.
 Charleston, WV

1999 - 2004 Patient Billing Supervisor
 CAMC Corporate Health Services
 South Charleston, WV

PROFESSIONAL AFFILIATIONS:

Association of Clinical Research Professionals

CERTIFICATIONS:

ACRP/Certified Clinical Research Coordinator – 2005 / 2008

Basic Life Support – 2007

CITI – Course in The Protection of Human Research Subjects – 2005

Conducting Clinical Research Seminar – 2002 & 2005

Phlebotomy Skills Training – 2003

Transportation of Dangerous Goods – 2005

GCP Guideline-Conduction a Clinical Research Study 2-day Training – 2005

NCCLS Venipuncture and Skin Puncture Procedures /Phlebotomy Skills Training – 2004

Transportation of Dangerous Goods Certified – 2005

CLINICAL RESEARCH EXPERIENCE:

8 Years of Research Experience to date

Clinical Trials Financial Analyst: the primary role of the Financial Analyst is to communicate with potential and active sponsors, coordinate pre-study site visits and responsible for all financial information (i.e., contracts, budgets, processing of bills and payments etc.) between the Clinical Trials Center and the sponsoring company of the study. Provides back-up coordination support when needed.

Clinical Research Coordinator: the primary role of the Research Coordinator is to screen and assess the patients in accordance with the protocol for eligibility, baseline, and follow-up procedures. The research coordinator is also responsible for assisting in the informed consent process, completing all case report forms, collecting the data, and maintaining documents and correspondence with the sponsor. The coordinator also completes all internal and external regulatory requirements.

HS# 06-011-1868: *SCI* - A 15-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin for the Treatment of Chronic Central Naturopathic Pain After Spinal Cord Injury, *Pfizer Inc.*

HS# 04-01-1557: *PEDS 1-5* - A Double-Blind, Randomized, Multi-Center Study Followed by 12 Months Open-Label Treatment to Evaluate the Dose-Response and Safety of Valsartan in Pediatric Hypertensive Patients 1 - 5 Years of Age, *Novartis*

HS# 03-11-1540: *BOTOX* - A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study of Pulmonary Function in Patients with Reduced Lung Function Treated with

BOTOX(R) (Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper Limb Poststroke Spasticity, *Clinimetrics*

HS# 03-08-1509: 261B - Protocol Number 261B: A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age, *Astra Zeneca*

HS# 03-08-1508: 261A - Protocol Number 261A: A Dose Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, *Astra Zeneca*

HS# 03-07-1507: *SCI-F300-EXT* - Protocol #: SCI-F300-EXT: Open-Label Extension of Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Chronic, Incomplete Spinal Cord Injury, *Acordia Therapeutics*

HS# 02-12-1433: *ARDS* - A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Surfaxin(R) (Lucinactant) Delivered Via Bronchopulmonary Segmental Lavage to Standard of Care in Patients with Acute Respiratory Distress Syndrome (ARDS), *Discovery Laboratories, Inc.*

HS# 02-09-1406: *MOBILE* - A Prospective, Phase III, Randomized Trial to Evaluate the Safety and Effectiveness of the Novoste™ Corona™ System for the Treatment of In-Stent Restenosis of Native Superficial Femoral Arteries (SFA) and Popliteal Arteries When Used Immediately After Successful Percutaneous Intervention (*MOBILE* Study), *Novoste Corporation*

HS# 02-05-1365: *SEPSIS* - Protocol #: M/1260/0080 Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream, *Pharmacia, Inc.*

HS# 02-04-1354: *SCI-F301* - Protocol SCI-F301: Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects with Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury, *Acordia Therapeutics, Inc.*

HS# 02-03-1343: *Peds Asthma* - Protocol #: XRP1526B-344 A Multicenter, Randomized, Open-Label, One Year Long-Term Safety Study of Ciclesonide Metered Dose Inhaler 50 micrograms/day to 200 micrograms/day (Ex-valve) administered once daily or Fluticasone Dry Powder Inhaler (Flovent(R) Rotadisk(R)) 50 micrograms or 100 micrograms Administered Twice Daily for the Treatment of Children with Persistent Asthma, *Aventis Pharmaceuticals*

HS# 01-07-1290: *COPD* - Protocol Number Protocol # SCO30003: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide/Viani/Advair) 50/500ug bd, Salmeterol 50ug bd and Fluticasone Propionate 500 ug bd, All Delivered via the Diskus/Accuhaler Inhaler, on the Survival of Subjects with Chronic Obstructive Pulmonary Disease (COPD) over 3 Years of Treatment, *Glaxo Wellcome R & D*

HS# 01-06-1286: *PERTUSSIS* - Protocol Number P3T06: Safety, Immunogenicity and Lot Comparability of CPDT Vaccine Adsorbed (Aventis Pasteur classic five-component pertussis vaccine in combination with tetanus and diphtheria toxoids adsorbed) When Administered with Other Recommended Vaccine at 2,4,6,15 to 16 Months of Age, *Aventis Pasteur*

HS# 02-07-1381: *NICALERT* - Protocol NICE TS0602 - NicAlert (TM) Urine and Saliva Study,

HS# 02-03-1346: *PLUS* - Protocol Number T3S201: A Randomized, Multicenter Trial of Transcutaneous, Low-Energy ultrasound Therapy with Thrombolysis for Patients with Acute Myocardial Infarction. PLUS Perfusion by Thrombolytic and UltraSound, *Timi3 Systems, Inc*

HS# 02-03-1345: *REPLACE 2* - Protocol TMC-BIV-01-03 A Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to reduced Clinical Events, Part 2, *The Medicines Company*

HS# 01-09-1302: *PARODI* - The Parodi Anti-Emboli System (PAES) as an adjuvant cerebral protection device during Carotid Stent-supported Angioplasty with the Boston Scientific Carotid Wallstent Monorail Endoprosthesis (Wallstent), *Arteria Medical Science, Inc.*

HS # 01-09-1301: *SHELTER*- Stenting of High Risk Patients: Extracranial Lesion Trial with Emboli Removal, *Boston Scientific Corporation*

HS# 01-04-1257: *EMBOLEX* -A multi-center clinical study of the safety of the EMBOL-X™ Intraaortic Filtration System in Patients undergoing coronary artery bypass grafting (CABG) or valve repair/ replacement surgery procedures requiring cardiopulmonary bypass, *EMBOLEX Inc.*

HS# 01-02-1237: *ACUTE PELVIC* - Protocol AI464-028: A Randomized, Double-Blind, Multi-Center, Comparative Phase III Study of Intravenous Ampicillin/Sulbactam Followed by Oral BMS-284756 Versus Intravenous Ampicillin/Sulbactam Followed by Oral Amoxicillin/Clavulanate in the Treatment of Acute Pelvic Infections, *Bristol-Myers Squibb*

HS# 01-01-1223: *PCPT* - Protocol Number SWOG 9217: Chemoprevention of Prostate Cancer with Finasteride (Proscar), Phase III, Intergroup Study (NCI), *Southwest Oncology Group*

HS# 01-01-1222: *SIRIUS* - Protocol Number P00-6302: A Multicenter, Randomized, Double-Blind Study of Sirolimus-Coated BX Velocity™ Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Disease Lesions,

HS# 99-05-1055: *STAR* - Protocol Number NSABP P-2: Study of Tamoxifen and Raloxifene for the Prevention of Breast Cancer, *National Surgical Adjuvant Breast and Bowel Project (NSABP)*

HS# 97-11-914: *NCGS* - Protocol Number 85-036: Genentech National Cooperative Growth Study (NCGS) Post Marketing Surveillance Program for Protropin® (Somatrem for Injection), Nutropin® Somatropin (rDNA Origin) for Injection, *Genentech, Inc.*

+++ HS# is Internal study Identifier